Novartis AG or Bio-Techne Corporation: Who Manages SG&A Costs Better?

Managing SG&A Costs: Novartis AG vs. Bio-Techne Corporation

In the competitive landscape of the pharmaceutical and biotechnology sectors, managing Selling, General, and Administrative (SG&A) expenses is crucial for maintaining profitability. Over the past decade, Novartis AG and Bio-Techne Corporation have demonstrated contrasting approaches to SG&A cost management.

From 2014 to 2023, Novartis AG consistently reported SG&A expenses averaging around $14.5 billion annually, with a notable decrease to $12.5 billion in 2023. This represents a 14% reduction, indicating a strategic shift towards cost efficiency. In contrast, Bio-Techne Corporation's SG&A expenses have steadily increased, peaking at nearly $400 million in 2024, a 550% rise from 2014.

While Novartis AG's recent cost-cutting measures suggest a focus on lean operations, Bio-Techne's rising expenses may reflect aggressive growth strategies. The absence of 2024 data for Novartis AG leaves room for speculation on future trends.